Diabetes, High BMI, Previous Metformin Common in Teens With Rx for GLP-1 RAs
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 16, 2024 -- Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have comorbid type 2 diabetes, high body mass index, and a previous metformin prescription, according to a research letter published online Oct. 16 in JAMA Network Open.
Margaret G. Miller, from Case Western Reserve University in Cleveland, and colleagues characterized patient demographics and the prevalence of comorbid conditions among 11,380 matched patients (aged 10 to 17 years) who received or did not receive a first prescription for a GLP-1 RA during visits from 2019 to 2023.
The researchers found that patients prescribed GLP-1 RAs were more commonly female (60.4 percent; P < 0.001), Black or African American (27.9 percent; P < 0.001) and Hispanic or Latinx individuals (25.3 percent; P < 0.001), and less commonly White individuals (46.0 percent; P < 0.001). Among patients receiving GLP-1 RAs, preexisting International Statistical Classification of Diseases and Related Health Problems, Tenth Revision encounter diagnosis codes of type 2 diabetes (46.2 percent), metabolic syndrome (16.0 percent), and type 1 diabetes (18.6 percent) were more common than among controls. Body mass index ≥95th percentile was more common among patients receiving a GLP-1 RA than those who did not (87.1 versus 32.9 percent). Two-thirds of patients receiving a GLP-1 RA prescription had a prior prescription for insulin, metformin, or orlistat.
“A deep understanding of the long-term impacts (i.e., physical, mental, sociocultural, etc.) of GLP-1 RAs on preadolescent and adolescent patients is crucial to better inform prescription practices and is an important direction for future studies,” the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D
THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause...
GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with...
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.